INZY — Inozyme Pharma Share News
0.000.00%
Last trade - 00:00- $257.60m
- $219.11m
Brief: Inozyme Pharma reports Q2 results
Brief: Inozyme Pharma Secures Flexible Debt Facility For Up To $70 Million With K2 Healthventures
Brief: Inozyme Pharma Announces Positive Preliminary Data From Phase 1/2 Clinical Trial Of INZ-701
Brief: Inozyme Pharma Announces Partnership With Rady Children's Institute For Genomic Medicine To Advance Newborn Screening For Genetic Diseases
Brief: Inozyme Pharma Appoints Kurt Gunter As Chief Medical Officer
Inozyme Pharma Inc reports results for the quarter ended in March - Earnings Summary
Brief: Inozyme Pharma Reports First Quarter 2022 Financial Results And Provides Business Highlights
Inozyme Pharma Inc expected to post a loss of 82 cents a share - Earnings Preview
Brief: Rock Springs Capital Management LP Reports 6.12% Passive Stake In Inozyme Pharma
Inozyme Pharma rises on $73 mln common stock, warrants offering
Brief: Inozyme Pharma Reports $73 Mln Underwritten Offering Priced At-The-Market
Brief: Inozyme Pharma Provides Update for Phase 1/2 Clinical Trials in ABCC6 Deficiency & ENPP1 Deficiency
U.S. STOCKS ON THE MOVE-SunPower, Snow Lake, Sea Ltd
Inozyme Pharma up as mineralization disorder drug shows promise
Brief: Inozyme Pharma Announces Positive Preliminary Data From Phase 1/2 Clinical Trial Of INZ-701 In Patients With ENPP1 Deficiency
Brief: Inozyme Pharma Reports Full Year 2021 Financial Results
Brief: Inozyme Pharma Inc - Appointment Of Sanjay S. Subramanian As Chief Financial Officer (CFO)
Brief: Inozyme Pharma Announces Dosing Of First Patient In First-In-Human Clinical Trial Of INZ-701 In Patients With ENPP1 Deficiency
Inozyme Pharma Inc reports results for the quarter ended in September - Earnings Summary